Ultragenyx Pharmaceutical Ownership | Who Owns Ultragenyx Pharmaceutical?


OverviewForecastRevenueFinancialsChartTranscripts

Ultragenyx Pharmaceutical Ownership Summary


Ultragenyx Pharmaceutical is owned by 92.25% institutional investors, 3.43% insiders, and 4.32% retail investors. Vanguard group is the largest institutional shareholder, holding 10.51% of RARE shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.04% of its assets in Ultragenyx Pharmaceutical shares.

RARE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockUltragenyx Pharmaceutical92.25%3.43%4.32%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group10.03M10.51%$422.17M
Blackrock funding, inc. /de6.54M6.84%$274.99M
Blackrock5.60M6.65%$230.30M
Sands capital management4.30M4.50%$180.82M
Rtw investments, lp3.26M3.87%$133.98M
State street2.70M3.20%$110.85M
Price t rowe associates inc /md/2.51M2.63%$105.70M
Wellington management group llp2.46M2.57%$103.39M
Clearbridge investments2.32M2.43%$97.70M
Federated hermes2.05M2.15%$86.24M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cutter capital management, lp406.80K7.01%$17.11M
Eagle health investments lp627.60K6.47%$26.40M
Vestal point capital, lp1.50M3.74%$63.10M
First light asset management763.61K3.07%$32.12M
Rock springs capital management lp1.74M2.79%$73.19M
Privium fund management b.v.251.60K2.63%$10.31M
Bioimpact capital391.02K2.34%$16.45M
Rtw investments, lp3.26M2.07%$133.98M
Sphera funds management228.78K1.74%$9.62M
Suvretta capital management1.15M1.65%$48.44M

Top Buyers

HolderShares% AssetsChange
Norges bank961.79K0.01%961.79K
Vestal point capital, lp1.50M3.74%750.00K
Blackrock funding, inc. /de6.54M0.01%707.67K
Deep track capital, lp653.51K1.03%653.51K
Pictet asset management sa1.17M0.05%653.09K

Top Sellers

HolderShares% AssetsChange
Rtw investments, lp3.26M2.07%-3.83M
Wellington management group llp2.46M0.02%-1.71M
Alkeon capital management1.69M0.14%-1.32M
Sands capital management4.30M0.54%-820.25K
Aqr capital management280.55K0.02%-763.83K

New Positions

HolderShares% AssetsChangeValue
Norges bank961.79K0.01%961.79K$40.46M
Deep track capital, lp653.51K1.03%653.51K$27.49M
Frazier life sciences management425.00K0.82%425.00K$17.47M
Fisher asset management265.19K0.00%265.19K$11.16M
Balyasny asset management109.90K0.01%109.90K$4.62M

Sold Out

HolderChange
Activest wealth management-1.00
Mather group, llc.-2.00
Concourse financial group securities-3.00
Caitlin john-5.00
Parkside financial bank & trust-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025319-4.20%88,821,8041.51%921.10%161-5.29%104-4.59%
Dec 31, 2024195-38.87%51,382,783-40.24%530.66%96-43.86%71-24.47%
Sep 30, 202431713.21%85,943,715-2.53%890.82%1724.88%9320.78%
Jun 30, 2024277-0.72%88,159,11611.50%1041.10%1637.95%75-5.06%
Mar 31, 202427911.16%79,067,043-1.61%970.78%1518.63%793.95%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF2.81M3.04%92.60K
Vanguard Total Stock Mkt Idx Inv2.85M3.04%67.92K
Sands Capital Select Growth TE Inst EQ2.61M2.82%520.56K
Vanguard Small Cap Index2.21M2.35%15.24K
Vanguard Explorer Inv2.00M2.16%-
Vanguard Institutional Extnd Mkt Idx Tr1.42M1.51%7.97K
Hartford MidCap Y1.28M1.39%-24.56K
Vanguard Small Cap Growth Index Inv1.23M1.31%-925.00
DWS Vermögensbildungsfonds I LD1.18M1.25%-6.00
Federated Hermes Kaufmann Small Cap A1.09M1.18%-

Recent Insider Transactions


DateNameRoleActivityValue
Apr 21, 2025Crombez Eric EVP and Chief Medical OfficerSell$8.50K
May 05, 2025Crombez Eric EVP and Chief Medical OfficerSell$20.40K
Mar 06, 2025Horn Howard Chief Financial OfficerSell$72.11K
Mar 03, 2025Kassberg Thomas Richard CBO & EVPSell$253.78K
Mar 03, 2025Parschauer Karah Herdman EVP and Chief Legal OfficerSell$540.82K

Insider Transactions Trends


DateBuySell
2025 Q2-2
2025 Q1-11
2024 Q4-3
2024 Q3-4
2024 Q2-4

RARE Ownership FAQ


Who Owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical shareholders are primarily institutional investors at 92.25%, followed by 3.43% insiders and 4.32% retail investors. The average institutional ownership in Ultragenyx Pharmaceutical's industry, Biotech Stocks , is 63.96%, which Ultragenyx Pharmaceutical exceeds.

Who owns the most shares of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s largest shareholders are Vanguard group (10.03M shares, 10.51%), Blackrock funding, inc. /de (6.54M shares, 6.84%), and Blackrock (5.6M shares, 6.65%). Together, they hold 24.00% of Ultragenyx Pharmaceutical’s total shares outstanding.

Does Blackrock own Ultragenyx Pharmaceutical?

Yes, BlackRock owns 6.65% of Ultragenyx Pharmaceutical, totaling 5.6M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 230.3M$. In the last quarter, BlackRock increased its holdings by 367.61K shares, a 7.02% change.

Who is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested?

Cutter capital management, lp is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested, with 7.01% of its assets in 406.8K Ultragenyx Pharmaceutical shares, valued at 17.11M$.

Who is the top mutual fund holder of Ultragenyx Pharmaceutical shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Ultragenyx Pharmaceutical shares, with 3.04% of its total shares outstanding invested in 2.81M Ultragenyx Pharmaceutical shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools